Zoetis Inc. $ZTS Shares Acquired by Schroder Investment Management Group

Schroder Investment Management Group increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 13.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 162,002 shares of the company’s stock after acquiring an additional 19,117 shares during the period. Schroder Investment Management Group’s holdings in Zoetis were worth $23,704,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC increased its holdings in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. Financial Consulate Inc. purchased a new position in Zoetis during the third quarter valued at $39,000. SJS Investment Consulting Inc. grew its position in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares during the period. TruNorth Capital Management LLC acquired a new stake in shares of Zoetis in the third quarter valued at about $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Zoetis during the third quarter worth about $46,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $115.25 on Friday. The firm has a 50-day simple moving average of $125.54 and a 200-day simple moving average of $132.19. The stock has a market capitalization of $48.65 billion, a price-to-earnings ratio of 19.14, a price-to-earnings-growth ratio of 1.83 and a beta of 0.95. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 52 week low of $115.23 and a 52 week high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same period last year, the firm posted $1.40 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Wall Street Analyst Weigh In

ZTS has been the subject of several research analyst reports. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. HSBC set a $140.00 price objective on Zoetis in a report on Wednesday, December 10th. UBS Group set a $136.00 target price on Zoetis in a report on Thursday, January 29th. BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Finally, Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.